NEW YORK, Dec 13, 2007 Forest Laboratories, Inc. announced today that it has received notification from several companies that they have filed Abbreviated New Drug Applications (ANDA) with Paragraph IV Certifications to obtain approval to market generic equivalents of Namenda, an NMDA receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer's type. The Company intends to pursue all appropriate legal action to defend its intellectual property related to Namenda. Namenda is covered by an issued U.S. patent which is set to expire in April 2010. Forest has applied for patent term restoration which, if granted, would extend Namenda's patent protection until September 2013.
Saturday, 15 December 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment